Mazen Animal Health - Oral Vaccines
Mazen Animal Health - Oral Vaccines is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Mazen Animal Health - Oral Vaccines.
Mazen Animal Health - Oral Vaccines is a company.
Key people at Mazen Animal Health - Oral Vaccines.
Mazen Animal Health is a biotechnology company developing plant-based, orally delivered vaccines for the animal health industry, using corn seeds as a biofactory to produce antigens integrated into animal feed.[1][2][3] It targets livestock diseases like Porcine Epidemic Diarrhea Virus (PEDV) in swine and Coccidiosis in poultry, serving farmers by solving labor-intensive injection challenges, reducing antibiotic use, and providing cost-effective protection passed through maternal milk or feed.[1][3] The company has shown strong growth momentum, raising $2M in seed funding, $12M in Series A (led by Fall Line Capital in 2022), and securing grants like a 2024 Iowa award for African Swine Fever research, while expanding facilities in North Carolina, Illinois, and California and growing its team to 21 employees.[2][3]
Mazen Animal Health was founded in 2016 by CEO Jenny Filbey, PhD, and co-founder John Howard, a leading expert in recombinant protein production in plants whose research originated at Cal Poly's Tech Park over nearly two decades.[2][3][4] The idea emerged from Howard's breakthrough work on molecular farming, leveraging Iowa's corn, pork, and poultry strengths to create edible vaccines that address injection-related labor, safety, and efficacy issues in livestock.[1][3] Early traction included angel investments totaling $1.3M, a $2M Series Seed round with SBDC support proving oral vaccine efficacy in sow trials (protecting piglets from PEDV), and pivotal partnerships like Kent Corporation for market advancement.[2][3]
Mazen rides the agbiotech trend toward sustainable animal health, aligning with molecular farming to produce biologics at scale amid rising demand for antibiotic alternatives and efficient livestock solutions in a $5B+ global vaccine market.[1][3][4] Timing is ideal post-2022 funding amid pork/poultry production pressures from diseases like PEDV (high piglet mortality) and Coccidiosis (gut lesions managed via antibiotics), with Iowa's corn dominance and investor ecosystem accelerating commercialization.[3] Market forces favoring Mazen include regulatory pushes for reduced antibiotics, labor shortages on farms, and climate-resilient supply chains via stable, transport-easy vaccines; it influences the ecosystem by pioneering cross-species platforms (livestock to pets/wildlife), fostering Iowa/NC agtech hubs, and partnering with ventures like Kent for faster market entry.[3][4]
Mazen is poised for regulatory approvals and commercialization of PEDV/Cocci vaccines, with capital fueling scale-up, pipeline expansion (e.g., aquaculture, ASF), and team growth beyond 21 employees.[3] Trends like precision ag, foreign disease preparedness, and plant-made pharma will propel it, potentially capturing significant share in swine/poultry markets while evolving into a multi-species leader. As oral vaccines redefine prevention over treatment, Mazen's corn-based innovation—born from Cal Poly research and proven in trials—positions it to transform animal health economics and sustainability, delivering the cost-effective protection livestock producers need.
Key people at Mazen Animal Health - Oral Vaccines.
